Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVIRNASDAQ:AVTENASDAQ:CTORNASDAQ:NGNE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVIRAtea Pharmaceuticals$2.55-3.0%$2.92$2.51▼$4.15$218.23M0.17307,965 shs507,982 shsAVTEAerovate Therapeutics$8.61+0.3%$70.66$43.75▼$884.98$249.56M0.9518,261 shs81,973 shsCTORCitius Oncology$0.89-2.8%$0.74$0.55▼$4.42$63.70M-0.171.13 million shs71,189 shsNGNENeurogene$15.22-1.9%$13.43$6.88▼$74.49$217.07M1.56237,965 shs119,549 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVIRAtea Pharmaceuticals-3.04%-5.73%-13.27%-18.01%-35.61%AVTEAerovate Therapeutics+0.35%-14.67%-90.92%-90.00%-98.72%CTORCitius Oncology-2.83%+5.11%+34.12%-30.45%+89,029,900.00%NGNENeurogene-1.87%+9.81%+39.76%-18.91%-51.76%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVIRAtea Pharmaceuticals2.702 of 5 stars3.32.00.00.02.72.51.3AVTEAerovate Therapeutics1.5364 of 5 stars3.00.00.00.03.41.70.6CTORCitius OncologyN/AN/AN/AN/AN/AN/AN/AN/ANGNENeurogene2.3546 of 5 stars3.60.00.00.03.82.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVIRAtea Pharmaceuticals 2.50Moderate Buy$6.00135.29% UpsideAVTEAerovate Therapeutics 2.00Hold$78.75814.63% UpsideCTORCitius Oncology 3.00Buy$3.00236.97% UpsideNGNENeurogene 3.14Buy$46.20203.55% UpsideCurrent Analyst Ratings BreakdownLatest CTOR, AVIR, NGNE, and AVTE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025NGNENeurogeneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $45.004/14/2025NGNENeurogeneBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$45.00 ➝ $16.004/11/2025AVIRAtea PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$6.20 ➝ $6.003/25/2025NGNENeurogeneRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$38.003/25/2025NGNENeurogeneWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform3/25/2025NGNENeurogeneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$55.00 ➝ $50.003/7/2025AVIRAtea PharmaceuticalsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVIRAtea PharmaceuticalsN/AN/AN/AN/A$6.65 per shareN/AAVTEAerovate TherapeuticsN/AN/AN/AN/A$3.96 per shareN/ACTORCitius OncologyN/AN/AN/AN/A($0.22) per shareN/ANGNENeurogene$925K234.67N/AN/A$14.51 per share1.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVIRAtea Pharmaceuticals-$135.96M-$2.00N/AN/AN/AN/A-34.90%-32.38%N/AAVTEAerovate Therapeutics-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%N/ACTORCitius Oncology-$21.15MN/A0.00∞N/AN/A-43.67%-9.74%N/ANGNENeurogene-$36.32M-$4.35N/AN/AN/AN/A-32.81%-27.96%N/ALatest CTOR, AVIR, NGNE, and AVTE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q2 2025CTORCitius OncologyN/A-$0.11N/A-$0.11N/AN/A5/12/2025Q1 2025AVIRAtea Pharmaceuticals-$0.56-$0.40+$0.16-$0.40N/AN/A5/9/2025Q1 2025NGNENeurogene-$1.05-$1.08-$0.03-$1.08N/AN/A4/25/2025Q4 2024AVTEAerovate Therapeutics-$10.50-$3.15+$7.35-$0.09N/AN/A3/27/2025Q4 2024AVTEAerovate Therapeutics-$6.65-$6.65N/A-$0.19N/AN/A3/24/2025Q4 2024NGNENeurogene-$1.04-$0.99+$0.05-$0.99N/A$0.93 million3/6/2025Q4 2024AVIRAtea Pharmaceuticals-$0.35-$0.40-$0.05-$0.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVIRAtea PharmaceuticalsN/AN/AN/AN/AN/AAVTEAerovate TherapeuticsN/AN/AN/AN/AN/ACTORCitius OncologyN/AN/AN/AN/AN/ANGNENeurogeneN/AN/AN/AN/AN/ALatest CTOR, AVIR, NGNE, and AVTE DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/9/2025AVTEAerovate Therapeutics$84.004/29/20254/25/20254/28/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVIRAtea PharmaceuticalsN/A19.3319.33AVTEAerovate TherapeuticsN/A8.788.78CTORCitius Oncology0.080.340.08NGNENeurogeneN/A9.099.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVIRAtea Pharmaceuticals86.67%AVTEAerovate TherapeuticsN/ACTORCitius Oncology70.52%NGNENeurogene52.37%Insider OwnershipCompanyInsider OwnershipAVIRAtea Pharmaceuticals17.80%AVTEAerovate Therapeutics24.90%CTORCitius Oncology4.57%NGNENeurogene11.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVIRAtea Pharmaceuticals7085.58 million69.43 millionOptionableAVTEAerovate Therapeutics2028.99 million21.69 millionOptionableCTORCitius OncologyN/A71.55 million55.17 millionN/ANGNENeurogene9014.26 million13.38 millionOptionableCTOR, AVIR, NGNE, and AVTE HeadlinesRecent News About These CompaniesDriehaus Capital Management LLC Sells 69,422 Shares of Neurogene Inc. (NASDAQ:NGNE)May 13 at 5:53 AM | marketbeat.comNeurogene (NASDAQ:NGNE) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPSMay 13 at 12:23 AM | marketbeat.comDAFNA Capital Management LLC Has $1.18 Million Position in Neurogene Inc. (NASDAQ:NGNE)May 10, 2025 | marketbeat.comDeerfield Management Company L.P. Series C Makes New Investment in Neurogene Inc. (NASDAQ:NGNE)May 10, 2025 | marketbeat.comNeurogene Reports First Quarter 2025 Financial Results and Highlights Recent UpdatesMay 9, 2025 | businesswire.comNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 8, 2025 | businesswire.comCasdin Capital LLC Grows Stake in Neurogene Inc. (NASDAQ:NGNE)May 8, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Invests $2.82 Million in Neurogene Inc. (NASDAQ:NGNE)May 8, 2025 | marketbeat.comNeurogene (NGNE) Expected to Announce Quarterly Earnings on FridayMay 8, 2025 | americanbankingnews.comBaker BROS. Advisors LP Boosts Holdings in Neurogene Inc. (NASDAQ:NGNE)May 6, 2025 | marketbeat.comArrowMark Colorado Holdings LLC Has $10.26 Million Stock Position in Neurogene Inc. (NASDAQ:NGNE)May 6, 2025 | marketbeat.comNeurogene (NGNE) Expected to Announce Earnings on FridayMay 4, 2025 | marketbeat.comSamsara BioCapital LLC Acquires 449,337 Shares of Neurogene Inc. (NASDAQ:NGNE)May 2, 2025 | marketbeat.comNeurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual MeetingApril 28, 2025 | businesswire.comRock Springs Capital Management LP Invests $2.18 Million in Neurogene Inc. (NASDAQ:NGNE)April 23, 2025 | marketbeat.comNeurogene Inc. (NASDAQ:NGNE) Shares Bought by Walleye Capital LLCApril 22, 2025 | marketbeat.comNeurogene Inc. (NASDAQ:NGNE) Given Average Rating of "Buy" by BrokeragesApril 21, 2025 | marketbeat.comBMO Capital Markets Has Lowered Expectations for Neurogene (NASDAQ:NGNE) Stock PriceApril 16, 2025 | marketbeat.comJPMorgan Chase & Co. Purchases 476,418 Shares of Neurogene Inc. (NASDAQ:NGNE)April 16, 2025 | marketbeat.comNeurogene modifie son accord avec Baker Bros pour augmenter le seuil de nominationApril 15, 2025 | zonebourse.comNeurogene price target lowered to $16 from $45 at BMO CapitalApril 14, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesThese 3 Cybersecurity Stocks Are Defying the DownturnBy Ryan Hasson | April 29, 2025View These 3 Cybersecurity Stocks Are Defying the DownturnGoogle Is Betting Big on Nuclear Reactors—Should You?By Dan Schmidt | May 9, 2025View Google Is Betting Big on Nuclear Reactors—Should You?BigBear.ai: A Short-Squeeze Is Possible, a Sharp Drop Is LikelyBy Thomas Hughes | May 1, 2025View BigBear.ai: A Short-Squeeze Is Possible, a Sharp Drop Is LikelyAT&T, Verizon & T-Mobile: Who Won the Big 3 Telecom Battle in Q1?By Leo Miller | May 1, 2025View AT&T, Verizon & T-Mobile: Who Won the Big 3 Telecom Battle in Q1?Why Institutions Are Buying Super Micro Computer Stock AgainBy Gabriel Osorio-Mazilli | April 28, 2025View Why Institutions Are Buying Super Micro Computer Stock AgainCTOR, AVIR, NGNE, and AVTE Company DescriptionsAtea Pharmaceuticals NASDAQ:AVIR$2.55 -0.08 (-3.04%) As of 05/14/2025 04:00 PM EasternAtea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.Aerovate Therapeutics NASDAQ:AVTE$8.61 +0.03 (+0.35%) As of 05/13/2025Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Citius Oncology NASDAQ:CTOR$0.89 -0.03 (-2.83%) As of 05/14/2025 04:00 PM EasternCitius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.Neurogene NASDAQ:NGNE$15.22 -0.29 (-1.87%) As of 05/14/2025 04:00 PM EasternNeurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
